Intravenous versus subcutaneous immunoglobulin – Authors' reply
File version
Author(s)
Mielke, O
Sabet, A
George, K
Roberts, L
Carne, R
Blum, S
Henderson, R
Van Damme, P
Demeestere, J
Larue, S
Pinard D'Amour, CA
Bril, V
Breiner, A
et al.
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
License
Abstract
We thank Ravi Uniyal and colleagues for their comments on our results from the PATH trial1 on subcutaneous immunoglobulin (SCIg) for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP). They express concern about the relapse rates in the treatment groups and hypothesise the cause being the pharmacokinetics of SCIg.
Journal Title
The Lancet Neurology
Conference Title
Book Title
Edition
Volume
17
Issue
5
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Clinical sciences
Neurosciences
Persistent link to this record
Citation
van Schaik, IN; Mielke, O; Sabet, A; George, K; Roberts, L; Carne, R; Blum, S; Henderson, R; Van Damme, P; Demeestere, J; Larue, S; Pinard D'Amour, CA; Bril, V; Breiner, A; et al., Intravenous versus subcutaneous immunoglobulin – Authors' reply, The Lancet Neurology, 2018, 17 (5), pp. 393-394